HAE-C1-INH therapies such as plasma-derived C1-INH concentrate (pdC1-INH) and the bradykinin B2 receptor antagonist, icatibant, are used to resolve AAE-C1-INH attacks [16]. This evidence concerns the gene SERPING1 and hereditary angioedema.